Aug 5, 2026 · 7 min
Strong sales fail to lift SpaceX and AMD
Stock Movers: SPCX, DIS, LLY (Podcast)
The episode shows how investor reactions can diverge sharply from headline earnings when expectations, business mix, and growth prospects shape stock moves.
- 1SpaceX shares plunged despite beating expectations, underscoring how strong results can still disappoint investors.
- 2AMD reported record sales but saw its stock fall as markets looked beyond the headline growth.
- 3Disney benefited from entertainment profits, while Eli Lilly gained on surging demand for weight-loss drugs.
Don't miss
The sharpest contrast comes from SpaceX and AMD, whose strong sales and earnings still failed to prevent stock declines.
The brief
A busy earnings morning on Wall Street sets up a comparison of four companies whose results produced sharply different stock-market reactions.
Nathan Hager and Alexis Christophorous explain why SpaceX shares plunged despite beating expectations, showing that strong performance can still fall short of investor hopes.
AMD faces a similar disconnect: record sales are followed by a pre-market decline as investors weigh the results against what they expected from the chipmaker.
Disney gains support from entertainment profits in theme parks and streaming, while Eli Lilly benefits from soaring demand for its weight-loss drugs.
The episode’s central lesson is that earnings move stocks through expectations and investor interpretation, not simply through whether a company reports strong sales.
What was said on this episode
6 statements · 3 positive · 3 negative
SpaceX stock may experience more volatility.
“More volatility could be in store.”
Listen at 1:58
The expiring lockup could put further downward pressure on SpaceX stock.
“potentially putting more downward pressure on the stock”
Listen at 2:07
The rise of AI agents is driving unprecedented demand for AMD processors.
“the rise of AI agents continues to drive this unprecedented wave of demand”
Listen at 2:27
Softer-than-expected U.S. streaming advertising will affect Disney’s current quarter.
“softer than expected advertising for its U.S. streaming platform”
Listen at 3:43
Eli Lilly’s revenue growth was driven primarily by Mounjaro and Zepbound.
“driven primarily by its weight loss drugs Mounjaro and Zepbound”
Listen at 4:02
Eli Lilly forecasts full-year revenue between $85 billion and $87 billion.
“Eli Lilly also boosting its revenue forecast for the full year. It now sees revenue coming in at between 85 and $87 billion.”
Listen at 4:07
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
Wall Street
Advanced Micro Devices, Inc. (AMD)
Walt DisneyListen to the full episode and explore every guest, topic, and moment on PodLume.